Trial · NCT02303184
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
NCT02303184, Phase 2, Completed, Clearside Biomedical, Inc.; results first posted 2021-02-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO. Trials, record NCT02303184. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02303184
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
- NCT number
- NCT02303184
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 46 participants, actual
- Lead sponsor
- Clearside Biomedical, Inc.
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- 4 mg CLS-TA, Sham, IVT aflibercept
- First posted
- 2014-11-27
- Last updated
- 2021-02-08
- Results first posted
- 2021-02-08
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | 3 months |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | 3 months | The Intent-to-Treat set included all randomly assigned subjects who were treated and had at least one post-Baseline assessment. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal CLS-TA + IVT Aflibercept | 0 | 18 | Participants | |
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal Sham + IVT Aflibercept | 0 | 7 | Participants | |
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal CLS-TA + IVT Aflibercept | 1 | 3 | Participants | |
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal Sham + IVT Aflibercept | 1 | 12 | Participants | |
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal CLS-TA + IVT Aflibercept | 2 | 0 | Participants | |
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal Sham + IVT Aflibercept | 2 | 1 | Participants | |
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal CLS-TA + IVT Aflibercept | 3 | 2 | Participants | |
| Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm | Suprachoroidal Sham + IVT Aflibercept | 3 | 3 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Suprachoroidal CLS-TA + IVT Aflibercept | 23 | |
| Overall Study | STARTED | Suprachoroidal Sham + IVT Aflibercept | 23 | |
| Overall Study | COMPLETED | Suprachoroidal CLS-TA + IVT Aflibercept | 23 | |
| Overall Study | COMPLETED | Suprachoroidal Sham + IVT Aflibercept | 23 | |
| Overall Study | NOT COMPLETED | Suprachoroidal CLS-TA + IVT Aflibercept | 0 | |
| Overall Study | NOT COMPLETED | Suprachoroidal Sham + IVT Aflibercept | 0 |
Source ClinicalTrials.gov
Adverse events66
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Suprachoroidal CLS-TA + IVT Aflibercept | 1 | 23 | 1 |
| other | Vertigo | Ear and labyrinth disorders | Suprachoroidal Sham + IVT Aflibercept | 0 | 23 | 0 |
| other | Cataract | Eye disorders | Suprachoroidal CLS-TA + IVT Aflibercept | 1 | 23 | 1 |
| other | Cataract | Eye disorders | Suprachoroidal Sham + IVT Aflibercept | 0 | 23 | 0 |
| other | Cataract | Eye disorders | Suprachoroidal CLS-TA + IVT Aflibercept | 0 | 23 | 0 |
| other | Cataract | Eye disorders | Suprachoroidal Sham + IVT Aflibercept | 1 | 23 | 1 |
| other | Conjunctival haemorrhage | Eye disorders | Suprachoroidal CLS-TA + IVT Aflibercept | 2 | 23 | 2 |
| other | Conjunctival haemorrhage | Eye disorders | Suprachoroidal Sham + IVT Aflibercept | 1 | 23 | 1 |
| other | Conjunctival hyperaemia | Eye disorders | Suprachoroidal CLS-TA + IVT Aflibercept | 2 | 23 | 2 |
| other | Conjunctival hyperaemia | Eye disorders | Suprachoroidal Sham + IVT Aflibercept | 0 | 23 | 0 |
1 to 10 of 66Source ClinicalTrials.gov
See all 66 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Suprachoroidal CLS-TA + IVT Aflibercept | 0 | 23 |
| Total, all-cause mortality | Suprachoroidal Sham + IVT Aflibercept | 0 | 23 |
| Total, other adverse events | Suprachoroidal CLS-TA + IVT Aflibercept | 12 | 23 |
| Total, other adverse events | Suprachoroidal Sham + IVT Aflibercept | 10 | 23 |
| Total, serious adverse events | Suprachoroidal CLS-TA + IVT Aflibercept | 0 | 23 |
| Total, serious adverse events | Suprachoroidal Sham + IVT Aflibercept | 0 | 23 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Suprachoroidal CLS-TA + IVT Aflibercept vs Suprachoroidal Sham + IVT Aflibercept: deaths from any cause | Trial comparisons |
| Suprachoroidal CLS-TA + IVT Aflibercept vs Suprachoroidal Sham + IVT Aflibercept: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02303184
GET https://conductscience.org/api/trials/v1/NCT02303184/events?page=2